Med. praxi. 2018;15(2):76-79 | DOI: 10.36290/med.2018.016

Maked hypertension – what we know about this disease

MUDr. Lenka Štégnerová, MUDr. Markéta Sovová, MUDr. Oldřich Masný, MUDr. Tereza Pokorná,, prof. MUDr. Eliška Sovová, Ph.D., MBA
Klinika tělovýchovného lékařství a kardiovaskulární rehabilitace FN a LF UP Olomouc

Masked hypertension (MH) is defined as an elevation of blood pressure (TK) above 140/90 mmHg when measured outside a doctor'spractice while the TK value is standard at the doctor's office. The term uncontrolled hypertension is used for patients withpersistent hypertension treated but not yet achieving target values in the home measurement. MH is still insufficiently diagnosedbecause patient’s physiological TK is not under a control outside the doctor’s practice although an increased cardiovascular risk isalmost comparable to persistent hypertension. The prevalence of MH is around 13%. At present, there is still insufficiently exploredpathophysiological relationship of MH, which needs attention.

Keywords: masked hypertension, heart functions, kidneys, thyroid gland, diabetes mellitus, stroke, sleep apnea

Published: May 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Štégnerová Markéta Sovová Oldřich Masný Tereza Pokorná L, Sovová E. Maked hypertension – what we know about this disease. Med. praxi. 2018;15(2):76-79. doi: 10.36290/med.2018.016.
Download citation

References

  1. Piepoli MF, Hoes AW, Agewall S, Albus C, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2016; 37(29): 2315-2381. DOI: 10.1093/eurheartj/ehw106 Go to original source...
  2. Mancia G, Fagard R, Narkiewicz K, Redón J, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Journal of Hypertension. 2013; 31(7): 1281-1357. DOI: 10.1097/01.hjh.0000431740.32696.cc Go to original source... Go to PubMed...
  3. Pickering TG, Davidson K, Gerin W, Schwartz JE. Masked hypertension. Hypertension. 2002; 40(6): 795-796. DOI: 10.1161/01.HYP.0000038733.08436.98 Go to original source... Go to PubMed...
  4. Franklin SS, O'Brien E, Staessen JA. Masked hypertension: understanding its complexity. European Heart Jouranal. 2017; 38(15): 1112-1118. DOI: 10.1093/eurheartj/ehw502 Go to original source...
  5. Xu T, Liu J, Zhu G, Liu J, Han S. Prevalence of prehypertension and associated risk factors among Chinese adults from a large-scale multi-ethnic population survey. BMC Public Health. 2016; 16(1): 1471-2458. DOI: 10.1186/s12889-016-3411-4 Go to original source... Go to PubMed...
  6. Sega R, Trocino G, Lanzarotti A, et al. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: Data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study). Circulation. 2001; 104(12): 1385-1392. DOI: 10.1161/hc3701.096100 Go to original source...
  7. Mancia G, Bombelli M, Facchetti R, et al. Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension. Journal of Hypertension. 2009; 27(8): 1672-1678. DOI: 10.1097/HJH.0b013e32832be5f9 Go to original source... Go to PubMed...
  8. Mancia G, Bombelli M, Facchetti R, et al. Madotto F, Quarti-Trevano F, Polo Friz H, Grassi G, Sega R. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension. 2009; 54(2): 226-232. DOI: 10.1161/HYPERTENSIONAHA.109.129882 Go to original source... Go to PubMed...
  9. Bobrie G, Clerson P, Menard J, Postel-Vinay N, Chatellier G, Plouin PF. Masked hypertension: a systematic review. Journal of Hypertension. 2008; 26(9): 1715-1725. DOI: 10.1097/HJH.0b013e3282fbcedf Go to original source... Go to PubMed...
  10. Ogedegbe G, Agyemang C, Ravenell JE. Masked hypertension: evidence of the need to treat. Current Hypertension Reports. 2010; 12(5): 349-355. DOI: 10.1007/s11906-010-0140-4 Go to original source... Go to PubMed...
  11. Lurbe E, Torro I, Alvarez V, Nawrot T, Paya R, Redon J, Staessen JA. Prevalence, persistence and clinical significance of masked hypertension in youth. Hypertension. 2005; 45(4): 493-498. DOI: 10.1161/01.HYP.0000160320.39303.ab Go to original source... Go to PubMed...
  12. Sheppard JP, Fletcher B, Gill P, Martin U, Roberts N, McManus RJ. Predictors of the Home-Clinic Blood Pressure Difference: A Systematic Review and Meta-Analysis. American Journal of Hypertension. 2016; 29 (5): 614-625. DOI: 10.1093/ajh/hpv157 Go to original source...
  13. Diaz KM, Veerabhadrappa P, Brown MD, Whited MC, Dubbert PM, Hickson D. Prevalence, determinants, and clinical significance of masked hypertension in a population-based sample of African Americans: the Jackson Heart Study. American Journal of Hypertension. 2015; 28(7): 900-908. DOI: 10.1093/ajh/hpu241 Go to original source... Go to PubMed...
  14. Martin U, Haque MS, Wood S, et al. Ethnicity and differences between clinic and ambulatory blood pressure measurements. American Journal of Hypertension. 2015; 28(6): 729-738. DOI: 10.1093/ajh/hpu211 Go to original source...
  15. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension vs. true normotension: a meta-analysis. Journal of Hypertension. 2007; 25(11): 2193-2198. DOI: 10.1097/HJH.0b013e3282ef6185 Go to original source... Go to PubMed...
  16. Agarwal R, Pappas MK, Sinha AD. Masked Uncontrolled Hypertension in CKD. Journal of the American Society of Nephrology. 2016; 27(3): 924-932. DOI: 10.1681/ASN.2015030243 Go to original source... Go to PubMed...
  17. Aung SM, Güler A, Güler Y, Karabay CY, Akdemir I. Two-dimensional speckle-tracking echocardiography-based left atrial strain parameters predict masked hypertension in patients with hypertensive response to exercise. Blood Pressure Monitoring. 2017; 22(1): 27-33. DOI: 10.1097/MBP.000000000000022 Go to original source... Go to PubMed...
  18. Tadic M, Cuspidi C, Vukomanovic V, Celic V, Tasic I, Stevanovic A, Kocijancic V. Does masked hypertension impact left ventricular deformation? Journal of the American Society of Hypertension. 2016; 10(9): 694-701. DOI: 10.1016/j.jash.2016.06.032. Go to original source... Go to PubMed...
  19. Hänninen, Marjo-Riitta A, Niiranen, Teemu J, Puukka, et al. Target organ damage and masked hypertension in the general population: the Finn-Home study. Journal of Hypertension. 2013; 31(6): 1136-1143. DOI: 10.1097/HJH.0b013e32835fa5dc Go to original source... Go to PubMed...
  20. Ogedebe G, Spruill TM, Sarpong DF, et al. Correlates of isolated nocturnal hypertension and target organ damage in a population-based cohort of African Americans: the Jackson Heart Study. American Journal of Hypertension. 2013; 26(8): 1011-1016. DOI: 10.1093/ajh/hpt064 Go to original source...
  21. Leitao CB, Canani LH, Kramer CK, Boza JC, Pinotti A, Gross JL. Masked hypertension, urinary albumin excretion rate, and echocardiographic parameters in putatively normotensive type 2 diabetic patients. Diabetes Care. 2007; 30(5): 1255-1260. DOI: 10.2337/dc06-2131 Go to original source...
  22. Pierdomenico SD, Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. American Journal of Hypertension. 2011; 24(1): 52-58. DOI: 10.1038/ajh.2010.203 Go to original source...
  23. Agarwal R, Sinha AD, Light RP. Toward a definition of masked hypertension and white-coat hypertension among hemodialysis patients. Clinical Journal of the American Society of Nephrology. 2011; 6(8): 2003-2008. DOI: 10.2215/CJN.02700311 Go to original source... Go to PubMed...
  24. Agarwal R. Albuminuria and masked uncontrolled hypertension in chronic kidney disease. Nephrology Dialysis Transplantation. 2016. DOI: 10.1093/ndt/gfw325 Go to original source...
  25. Drawz PE, Alper AB, Anderson AH, et al. Hypertension and Elevated Nighttime Blood Pressure in CKD: Prevalence and Association with Target Organ Damage. Clinical Journal of the American Society of Nephrology. 2016; 11(4):642-52. DOI: 10.2215/CJN.08530815 Go to original source... Go to PubMed...
  26. Hata J, Fukuhara M, Sakata S, et al. White-coat and masked hypertension are associated with albuminuria in a general population: the Hisayama Study. Hypertension Research. 2017. DOI: 10.1038/hr.2017.74. Go to original source... Go to PubMed...
  27. Zhao H, Zeng F, Wang X, Wang L. Prevalence, risk factors, and prognostic significance of masked hypertension in diabetic patients. Medicine (Baltimore). 2017; 96(43):e8363. doi: 10.1097/MD.0000000000008363. Go to original source... Go to PubMed...
  28. Ng CM, Yiu SF, Choi KL, Choi CH, Ng YW, Tiu SC. Prevalence and significance of white-coat hypertension and masked hypertension in type 2 diabetics. Hong Kong Medical Jornal. 2008; 14(6): 437-443.
  29. Mancia G, Bombelli M, Facchetti R et al. Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension. Journal of Hypertension 2009; 27(8): 1672-1678. DOI: 10.1097/HJH.0b013e32832be5f9 Go to original source... Go to PubMed...
  30. Franklin SS, Thijs L, Li Y et al. Masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension. 2013; 61(5): 964-971. DOI: 10.1161/HYPERTENSIONAHA.111.00289 Go to original source...
  31. Agarwal R, Pappas MK. Delayed systolic blood pressure recovery following exercise as a mechanism of masked uncontrolled hypertension in chronic kidney disease. Nephrology Dialysis Transplantation. 2017. DOI: 10.1093/ndt/gfw266 Go to original source...
  32. Salazar MR, Espeche WG, Leiva Sisnieguez BC, et al. Significance of masked and nocturnal hypertension in normotensive women coursing a high-risk pregnancy. Journal of Hypertension. 2016; 34(11): 2248-2252. DOI: 10.1097/HJH.0000000000001067. ISSN 0263-6352 Go to original source... Go to PubMed...
  33. Piantanida E, Gallo D, Veronesi G, et al. Masked hypertension in newly diagnosed hypothyroidism: a pilot study. Journal of Endocrinological Investigation. 2016; 39(10): 1131-1138. DOI: 10.1007/s40618-016-0488-7 Go to original source... Go to PubMed...
  34. Ateş ?, Altay M, Kaplan M, et al. Is thyroid function associated with masked hypertension? The Anatolian Journal of Cardiology. 2016; 16(8): 644. DOI: 10.14744/AnatolJCardiol.2016.7197 Go to original source...
  35. Saeed S, Waje-Andreassen U, Fromm A, ?ygarden H, Naess H, Gerdts E. Prevalence and covariates of masked hypertension in ischemic stroke survivors: the NorwegianStroke in the Young Study. Blood Pressure Monitoring. 2016; 21(4): 244-250. DOI: 10.1097/MBP.0000000000000190. Go to original source... Go to PubMed...
  36. Sova M, Sovová E, Hobzová M, Kamasová M, Kolek V. Studium souvislostí poruch spánku, obstrukční spánkové apnoe a vzniku a léčby arteriální hypertenze - módní vlna nebo dlouhodobý trend? Vnitřní lékařství. 2015; 61(1): 50-55.
  37. Sova M, Sovová E, Hobzová M, Kamasová M, Zapletalová J, Kolek V. The effect of continuous positive airway pressure therapy on the prevalence of masked hypertension in obstructive sleep apnea patiens. Biomedical Papers. 2015; 159(2): 277-282. DOI: 10.5507/bp.2014.063 Go to original source...
  38. Drager LF. New Challenges for Sleep Apnea Research: Simple Diagnostic Tools, Biomarkers, New Treatments and Precison Medicine. Sleep Science. 2017; 10(1): 55-56. DOI: 10.5935/1984-0063.20170009 Go to original source...
  39. Baguet JP, Barone-Rochette G, Tamisier R, Levy P, Pépin JL. Mechanisms of cardiac dysfunction in obstructive sleep apnea. Nature Reviews Cardiology. 2012; 9(12), 679-688. DOI: 10.1038/nrcardio.2012.141 Go to original source... Go to PubMed...
  40. Mazic S, Suzic Lazic J, Dekleva M, et al. The impact of elevated blood pressure on exercise capacity in elite athletes. International Journal of Cardiology 2015; 180: 171-177. DOI: 10.1016/j.ijcard.2014.11.125 Go to original source...
  41. Filipovský J. Hypertenze bílého pláště a maskovaná hypertenze. Vnitřní Lékařství. 2015; 61(5): 401-405. Go to PubMed...
  42. Widimský J, Sachová M. Maskovaná hypertenze. Vnitřní Lékařství. 2005; 51(6): 699-703.




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.